Autonomic Technologies Raises $38M For On-Demand Neurostim
This article was originally published in Start Up
Executive Summary
Paris-based Edmond de Rothschild Investment Partners was the major and lead financer of May's $38 million Series D round for Autonomic Technologies, which is developing the Pulsante microstimulator for on-demand treatment of cluster headache.
You may also be interested in...
Device/Diagnostics Quarterly Deal Statistics, Q2 2015
At $1.8 billion, Q2 device financing nearly doubled the Q1 total, mainly from an increase in IPOs and early VC rounds, and acquisitions were slightly higher at $4.7 billion. Diagnostics funding also increased to $784 million from Q1's $597 million, and Danaher's monster $13.8 billion buy of life sciences company Pall headlined the second quarter's $15.6 billion total in diagnostics M&A activity.
Novel Devices Penetrate Migraine Headache Market
Several new device-based therapies are emerging designed to fill the treatment gap for migraine suffers who do not respond to traditional migraine therapies. These novel treatments include a headband-like device designed to stimulate the trigeminal nerve and an image-guided intranasal interventional treatment.
Still Can’t Cancel That Gym Membership? FTC Proposes One Negative Option Rule To Rule Them All
The FTC published a notice of proposed rulemaking on 23 March to update its 1973 Negative Option Rule, which has become obsolete vis-à-vis new marketing strategies in today’s digital world. Proposed amendments would clarify, expand and consolidate negative option-related provisions currently dispersed across different FTC laws and regulations.